Pharmacological treatment of obesity

Authors

  • Magnolia Navarro-Falcón Instituto de Endocrinología y Nutrición ENDAMA, Hospital Sanitas CIMA. España
  • Ignacio Jáuregui-Lobera Instituto de Ciencias de la Conducta y Universidad Pablo de Olavide. Sevilla. España

DOI:

https://doi.org/10.19230/jonnpr.3636

Abstract

-

Downloads

Download data is not yet available.

References

OMS: Organización Mundial de la Salud [Internet]. Ginebra: [citado 2020 Feb 29]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/obesity-andoverweight.

National Institute for Health and Care Excellence (“NICE”) [Internet]. Londres. NICE guidance; c2018-2020. Obesity: identification, assessment and management Clinical guideline; 2014 Nov. [citado 2020 Feb 27]; [alrededor de 2 pantallas]. Disponible en: https://www.nice.org.uk/guidance/cg189/chapter/1-Recommendations#pharmacological-interventions.

Lecube A, Freitas P, Monereo S, Souto S, Tinahones F. Consenso Ibérico sobre el tratamiento farmacológico de la obesidad en el adulto: Posicionamiento de las Sociedades Española y Portuguesa para el Estudio de la Obesidad (SEEDO-SPEO) 2018. Disponible en: https://www.seedo.es/images/site/notasprensa/consenso_SEEDOSPEO_rueda_prensa_12_julio.pdf

Srivastava G, Apovian C. Current pharmacotherapy for obesity. Nature Reviews. Endocrinology; Jan 2018; 148 (1): 12-24.

Saunders K, Umashanker D, Igel L, Kumar R, Aronne L. Obesity Pharmacotherapy. Med Clin N Am 2018 (102): 135–148.

Tenorio C, Arana C, Novo C. Tratamiento farmacológico de la obesidad. Siete días médicos Revista de atención primaria. [Internet] 2019 Mar 15 [citado 2020 Feb 22]; 884: 14-6. Dsiponible en https://www.sietediasmedicos.com/actualidad/evidenciasen/item/7801-tratamiento-farmacologico-de-la- obesidad.

AEMPS: Agenci a Españo l a de Med icamentos y Pr oduc tos Sani t ar i o s: Madrid: c2008 [citado 2020 Feb 27]. Disponible en: https://www.aemps.gob.es/

FDA: U.S. Food and Drug Administration: New Hampshire: c:2019 [citado 2020 Feb 27]. Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs.

Downloads

Published

2020-07-02

Issue

Vol. 5 No. 12: (December 2020) JONNPR 2020;5(12): 1464-1729

Section

Editorial

License

All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.

The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.

You are free to:

Share — copy and redistribute the material in any medium or format

Adapt — remix, transform, and build upon the material

The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

NonCommercial — You may not use the material for commercial purposes.

ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License